FDA Registration for Acne Products
Why acne treatment is an OTC drug, the monograph actives, when an acne-adjacent product is a cosmetic, and the benzoyl peroxide benzene issue.
Key Takeaways
- Acne treatment = OTC drug — under the OTC acne monograph.
- Four permitted actives — benzoyl peroxide, salicylic acid, sulfur, resorcinol (with sulfur).
- Drug pathway — establishment registration, NDC/listing, Drug Facts, cGMP, OMUFA.
- No acne claim + no acne active = cosmetic — a plain cleanser (MoCRA).
- Benzoyl peroxide can form benzene — stability & benzene testing now matter.
- Registration ≠ approval — monograph compliance, not FDA approval.
Acne Is an OTC Drug — the Permitted Actives
| Active | Concentration | Notes |
|---|---|---|
| Benzoyl peroxide | 2.5–10% | GRASE; specific warnings (see benzene, below) |
| Salicylic acid | 0.5–2% | Also a cosmetic ingredient at non-acne use |
| Sulfur | 3–10% | Alone or in combination |
| Resorcinol (2%) / resorcinol monoacetate (3%) | — | Only in combination with sulfur |
Acne Drug vs Cosmetic Cleanser
| Cosmetic (no acne claim/active) | Drug (acne claim or active) |
|---|---|
| Cleanses skin; gentle cleanser "for acne-prone skin" | Treats / clears / prevents acne or breakouts |
| Hydrates; improves the look of skin | Contains benzoyl peroxide/salicylic acid for acne |
| "Reduces the appearance of blemishes" (near the line — review) | "Prevents pimples," "unclogs pores to treat acne" |
Benzoyl Peroxide & Benzene
Benzoyl peroxide (BPO) is an effective, monograph-approved acne active — but it can be chemically unstable and degrade into benzene, a known carcinogen, especially at elevated temperatures.
- 2024 petition — a third-party lab (Valisure) petitioned FDA over benzene formation in BPO products
- March 2025 FDA testing — FDA tested 95 acne products; most had undetectable or very low benzene, but a small number had elevated levels and were voluntarily recalled at the retail level (brands including Proactiv, La Roche-Posay, Walgreens, and SLMD, among others)
- FDA's read — the agency stated the cancer risk from the levels found was very low, and did not tell consumers to discard products unless expired
- Ongoing — FDA has pressed manufacturers to test BPO for benzene and address stability; more testing and results are expected
The OTC Drug Path for Acne Products
- Drug establishment registration (21 CFR Part 207) — annual renewal; U.S. Agent if foreign
- NDC labeler code + SPL drug listing — for each product
- Drug Facts label (21 CFR 201.66) — active/purpose, uses, warnings (BPO: irritation & sun sensitivity), directions
- Monograph-compliant actives/claims + cGMP + OMUFA
- For benzoyl peroxide: stability + benzene testing in the quality file
Common Acne Product Mistakes
- Treating an acne product as a cosmetic — acne treatment is a drug
- Off-monograph active or concentration without an NDA
- Missing or incorrect Drug Facts labeling
- Ignoring benzoyl peroxide stability & benzene testing
- Claims beyond the monograph
- Missing the U.S. Agent (foreign); "FDA approved" claims
Get Your Acne Product Compliant
FDA Registration Assistance classifies the product (acne drug vs cosmetic cleanser), then handles the OTC drug pathway for acne products: drug establishment registration, NDC labeler code and SPL drug listing, Drug Facts and monograph compliance, and a U.S. Agent for foreign facilities — and we flag the benzoyl peroxide benzene/stability considerations so your quality file reflects them. For non-medicated cosmetics we handle the MoCRA path.
Contact us at info@fdaregistrationassistance.com or call +1 (928) 275-8333 for a quote. An independent compliance firm serving 1,000+ companies across 135+ countries, with 15+ years of experience.
Frequently Asked Questions — Acne Products
1. Are acne products cosmetics or drugs?
A product that treats or prevents acne is an OTC drug, not a cosmetic - treating a skin condition is a drug claim. Acne drug products are regulated under FDA's OTC acne monograph, with permitted active ingredients (benzoyl peroxide, salicylic acid, sulfur, and resorcinol in combination with sulfur). A plain cleanser or moisturizer that just cleans or hydrates, with no acne claim and no acne active, is a cosmetic. The claim and the active decide it.
2. What are the permitted OTC acne active ingredients?
Under the OTC acne monograph, the permitted actives are benzoyl peroxide (2.5–10%), salicylic acid (0.5–2%), and sulfur (3–10%), plus resorcinol (2%) or resorcinol monoacetate (3%) only in combination with sulfur. Using one of these at the monograph concentration, with monograph-compliant claims and Drug Facts labeling, is what lets an acne product be marketed OTC without a separate approval. Other actives, or higher concentrations, require an approved application (NDA).
3. What registration does an acne product need?
The OTC drug pathway: drug establishment registration (21 CFR Part 207), an NDC labeler code, and an SPL drug listing for each product; a Drug Facts label (21 CFR 201.66); monograph-compliant actives and claims; cGMP manufacturing; and OMUFA facility fees - plus a U.S. Agent if the facility is foreign. Drug establishment registration renews annually. This is different from (and heavier than) the cosmetic MoCRA path that applies to a non-medicated cleanser.
4. Is benzoyl peroxide safe — what's the benzene issue?
Benzoyl peroxide (BPO) is an effective, monograph-approved acne active, but it can be chemically unstable and degrade into benzene - a known carcinogen - especially at elevated temperatures. In 2024 a third-party lab (Valisure) petitioned FDA over benzene formation in BPO products, and in March 2025 FDA tested 95 acne products: most had undetectable or very low benzene, but a small number had elevated levels and were voluntarily recalled at the retail level. FDA stated the cancer risk from the levels found was very low. The practical takeaway: BPO products need stability data, benzene testing, and appropriate storage.
5. Do I have to test my benzoyl peroxide product for benzene?
It has become an expected part of doing BPO responsibly. Following the 2024–2025 findings, FDA has pressed manufacturers to test BPO products for benzene and to address stability (benzene formation increases with heat and over time). So a BPO acne product should have stability studies, finished-product and shelf-life benzene testing, controlled storage/transport, and documentation. It's part of your safety and quality file, and a growing area of FDA attention.
6. Which acne products were recalled for benzene?
After FDA's March 2025 testing, a limited number of BPO products were voluntarily recalled for elevated benzene, including certain lots of products from brands such as Proactiv, La Roche-Posay (Effaclar Duo), Walgreens, and SLMD, among others. The recalls were at the retail level (removed from shelves and online), and FDA did not tell consumers to discard products unless expired. FDA has said it would continue testing and release fuller results, so the situation is evolving.
7. When is an acne-related product a cosmetic?
When it makes no acne (drug) claim and contains no acne active. A gentle cleanser "for acne-prone skin" that only cleanses, or a moisturizer that only hydrates, can be a cosmetic - but the wording matters: "cleanses skin" is cosmetic, while "clears breakouts," "treats acne," or "prevents pimples" is a drug claim. And if it contains benzoyl peroxide or salicylic acid at acne-active levels for an acne purpose, it's a drug regardless of soft wording. "Reduces the appearance of blemishes" sits near the line and should be reviewed.
8. Is salicylic acid always a drug?
Not always - it depends on purpose and claim. Salicylic acid used as an acne treatment (0.5–2%, with an acne claim) is an OTC acne drug active. The same ingredient used at low levels for exfoliation/appearance, without a drug claim, can be part of a cosmetic. So salicylic acid can be a drug active or a cosmetic ingredient depending on how it's used and what's claimed - which is exactly why the claim and intended use drive the classification.
9. What labeling does an acne drug product need?
A Drug Facts panel (21 CFR 201.66): active ingredient(s) and purpose (acne), uses, warnings, and directions. Benzoyl peroxide carries specific warnings (skin irritation/sensitivity and increased sun sensitivity), and combination products have their own required statements. The Drug Facts format and content are set by the monograph - it's not free-form marketing copy. Any cosmetic aspects follow cosmetic labeling, but the Drug Facts panel is required for the acne drug.
10. Can I sell an acne product at a higher-than-monograph strength?
Not over the counter under the monograph. The monograph sets the permitted actives and concentration ranges (e.g., benzoyl peroxide 2.5–10%). Going outside those ranges, using a non-monograph active, or making claims beyond the monograph means the product is no longer covered by the monograph and would need an approved application (NDA) - a prescription/approval route. Most OTC acne brands stay within the monograph to avoid that.
11. Do foreign acne product brands need to register?
Yes. Any acne drug product marketed in the U.S. must comply regardless of where it's made, and foreign facilities need a U.S. Agent. A foreign acne drug registers as a drug establishment (with NDC/listing, Drug Facts, monograph compliance) and appoints a U.S. Agent; a foreign non-medicated cleanser (cosmetic) registers under MoCRA with a U.S. Agent. Imported acne products - especially BPO - are subject to scrutiny for compliance and, increasingly, benzene.
12. Does "natural" acne product still need to comply?
Yes. "Natural" doesn't change regulatory status. If a "natural" product treats acne, it's an OTC drug and needs the drug pathway - and if it uses a monograph active (like sulfur or salicylic acid) for acne, that's a drug active. A natural product with no acne claim and no acne active can be a cosmetic. The term describes marketing, not compliance.
13. Does registering my acne product mean it's FDA-approved?
No. OTC monograph drugs (like a compliant benzoyl peroxide or salicylic acid acne product) are "compliance, not approval" - they don't receive an individual FDA approval; they comply with the monograph. So calling an acne product "FDA-approved" is misleading. The accurate statement is that your facility is registered, your product is listed, and it complies with the OTC acne monograph.
14. What are the most common acne product mistakes?
Treating an acne product as a cosmetic (acne treatment is a drug); using a non-monograph active or off-range concentration without an NDA; missing or incorrect Drug Facts labeling; ignoring benzoyl peroxide stability and benzene testing; making claims beyond the monograph; missing the U.S. Agent (foreign); and "FDA approved" claims. Most trace back to not treating acne products as the OTC drugs they are - and, for BPO, not managing the benzene/stability risk.
15. Are prescription acne treatments different?
Yes. Prescription acne treatments (for example topical retinoids like tretinoin or adapalene at prescription strengths, oral antibiotics, or isotretinoin) are approved drugs on the NDA/prescription route, not the OTC monograph. This page is about OTC acne products under the monograph. If your product's active or strength isn't in the monograph, or it's intended to be prescription, it's on the approved-application path - a different and more involved process.
16. How does FDA Registration Assistance help acne product brands?
We classify the product (acne drug vs cosmetic cleanser), then handle the OTC drug pathway for acne products: drug establishment registration, NDC labeler code and SPL drug listing, Drug Facts and monograph compliance, and a U.S. Agent for foreign facilities - and we flag the benzoyl peroxide benzene/stability considerations so your quality file reflects them. For non-medicated cosmetics we handle the MoCRA path. We're an independent compliance firm serving 1,000+ companies across 135+ countries with 15+ years of experience. Contact info@fdaregistrationassistance.com or +1 (928) 275-8333.
